RANCHO CORDOVA, Calif., Sept. 7, 2012 (GLOBE NEWSWIRE) -- ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of enabling technologies for the processing, storage and administration of cell therapies, today said that it will be participating in the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 11. The Company's presentation by Matthew T. Plavan, Chief Executive Officer, will begin at 11:15 a.m., Eastern Daylight Time (8:15 a.m., Pacific Daylight Time). The presentation will be webcast live and archived for 90 days, streaming video and PowerPoint slides. Access is available by logging on to the conference website http://www.wsw.com/webcast/rrshq22/kool and via the Company's website at www.thermogenesis.com. About ThermoGenesis Corp. ThermoGenesis Corp. ( www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:
- The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
- AXP® AutoXpress® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP® MarrowXpress® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells from bone marrow aspirates in the laboratory setting.
- The Res-Q® 60 BMC/PRP (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).
CONTACT: Investor Relations +1-916-858-5107, or Email: email@example.com